Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Scandinavian Journal of Clinical and Laboratory Investigation|October 1, 1989
Plasma volume substitution does not inhibit plasma noradrenaline and muscle nerve sympathetic responses to insulin-induced hypoglycaemia in healthy humansH Frandsen, C Berne, J Fagius, et al.
Scandinavian Journal of Rehabilitation Medicine|November 24, 1998
The subacromial impingement syndrome. A study of results of treatment with special emphasis on predictive factors and pain-generating mechanismsH Rahme, E Solem-Bertoft, C E Westerberg, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 11, 2022
Short-term prediction of secondary progression in a sliding window: A test of a predicting algorithm in a validation cohortB Skoog, J Link, H Tedeholm, et al.
The American Journal of Physiology|November 1, 1989
Muscle sympathetic activity and norepinephrine release during mental challenge in humansP Hjemdahl, J Fagius, U Freyschuss, et al.
Archives of Neurology|March 1, 1982
Treatment of the Guillain-Barré syndrome by plasmapheresisP O Osterman, J Fagius, J Säfwenberg, et al.
Lancet (London, England)|December 8, 1984
Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathyP O Osterman, J Fagius, G Lundemo, et al.
Epilepsia|July 1, 1995
Positron emission tomography with [11C]deuterium-deprenyl in temporal lobe epilepsyE Kumlien, M Bergström, A Lilja, et al.
The International Journal of Artificial Organs|May 1, 1984
Plasma exchange in patients with Guillain-Barré syndrome: clinical improvement in patients with serum IgG antibodies to peripheral nerve tissueH Nyland, C A Vedeler, R Matre, et al.
Journal of Neurology|January 1, 1982
The clinical effect and the effect on serum IgG antibodies to peripheral nerve tissue of plasma exchange in patients wit Guillain-Barré syndromeC A Vedeler, H Nyland, J Fagius, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 6, 2012
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugsH Tedeholm, J Lycke, B Skoog, et al.
Pageof 7